Kidney Stones

“The take home message would be that in patients with prior history of kidney stone episodes…receiving 24-hour urine testing prior to starting pharmacologic preventive therapy is associated with a lower probability of a subsequent stone-related event,” says Ryan Hsi, MD, FACS.

In this interview, Caleb Nelson, MD, PhD, discusses the current state of evaluation and treatment of stones in pediatric patients.

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

Gregory Tasian, MD, MSc, MSCE, and Jason Kaufman co-authored a study that investigated the association between kidney stone presentations in South Carolina under 2 different climate change scenarios.

The designation was awarded to the Acoustic Enhancer, a micro bubble composed of a gas core with a lipid shell, which is intended for use in conjunction with standard laser lithotripsy.

“I think there is an urgency for us as urologists who are seeing many of these patients with kidney stones to be advocates, not just for the patients whom we're treating today, but for the populations in the future,” says Gregory Tasian, MD, MSc, MSCE.

"The devices, telemedicine and remote care, and outpatient surgery risk us losing the human connection we had with the patient, as time spent with them is at a premium today," writes Gopal H. Badlani, MD.

“The main question we were interested in answering was what the impact of future climate under different scenarios of climate change would have on the incidence of kidney stone disease, using South Carolina as a model state,” says Jason Kaufman.

"Our analysis suggests that a warming planet will likely cause an increased burden of kidney stone disease on health care systems,” says Gregory E. Tasian, MD, MSc, MSCE.

Investigators evaluated data from the Continuous National Health and Nutrition Examination Survey.

“Going into this study, we thought that potentially patients who had a stent placed with the string left in place were at higher risk of having a complication…But we found that they weren't at higher risk of a complication,” says Amy E. Krambeck, MD.

In a cohort of nearly 30,000 patients, more than half had cystoscopy-based stent removal within 6 months post ureteroscopy, investigators reported.

“I currently make regular use of a peripheral nerve block during PCNL…with the intent of, of limiting my patients exposure to and the need for opioids,” says Jared S. Winoker, MD.

“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.

“We should really try to adapt, know what we're doing to the specific patient based on their risk factors, prepare them appropriately, and understand that it's a dangerous complication. We should do everything we can to prevent it,” says Naeem Bhojani, MD, FRCSC.

“The most notable finding unquestionably was that peripheral nerve blocks have the ability to significantly reduce opioid requirements without compromising any pain control,” says Jared S. Winoker, MD.

In 2 recent studies led by Naeem Bhojani, MD, FRCSC, and Ben H. Chew, MD, MSc, investigators performed a meta-analysis to identify predictors of sepsis as well as the cost of sepsis for patients with stone disease.

“Ideally…we have a technology that's noninvasive that we can use in the clinic, where they don't require any anesthesia to…break the stones and make them smaller,” says Mathew D. Sorensen, MD, MS, FACS.

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

"Each bill that is submitted for reimbursement must have a code for both the service performed and a reason for the service," writes Jonathan Rubenstein, MD, and Mark Painter.

Get ready for the 2021 AUA annual meeting with this preview of non-malignant topics.

In this interview, Nicole L. Miller, MD, discusses her institution’s enhanced recovery after surgery protocol for ureteroscopy, which eliminates the use of opioids in patients undergoing this common procedure.

Amy E. Krambeck, MD, discusses her recent trial comparing the efficacy of Trilogy and ShockPulse-SE lithotripters used in percutaneous nephrolithotomy.

“For harder, more aggressive stones, I'm more likely to use the Trilogy based on the results of the study. If I have a softer, easier stone, I prefer the lightness of the ShockPulse," said lead study investigator Amy E. Krambeck, MD.

The FDA approved lumasiran in November 2020 as the first drug for the treatment of patients with primary hyperoxaluria type 1.